**C.V.**

الاسم : علي عادل داؤد محمد النعيمي

تاريخ الميلاد: 1/11/1966

مكان الميلاد : الموصل

الحالة الاجتماعية: متزوج

عدد الأطفال : 5

الجنسية : عراقية

الديانة : مسلم

العنوان : حي الميثاق، الموصل، العراق

جوال : 9647701768002

فايبر : 9647701768002

aad@uomosul.edu.iq، aliadeldawood@gmail.comالبريد الالكتروني :

https://www.researchgate.net/profile/Ali\_Dawood: ResaerchGateموقع

W-7213-2018 معرف الباحث:

معرف أوركيد https://orcid.org/0000-0001-8988-5957

[https://www.scopus.com/authid/detail.uri؟authorId=57211311855معرف](https://www.scopus.com/authid/detail.uri%D8%9FauthorId%3D57211311855%D9%85%D8%B9%D8%B1%D9%81) سكوبس:

رقم التعريف: 57211311855

اللغة : العربية والإنجليزية

الهوايات : القراءة

المهنة والعنوان: مدرس ، كلية الطب ، الموصل ، العراق

الشهادات: 1- دكتوراه في الأحياء المجهرية ، كلية العلوم ، جامعة الموصل 2015.

2- ماجستيرفي التكنولوجيا الحيوية ، كلية العلوم الحيوية والهندسة الحيوية ، جامعة التكنولوجيا ماليزيا 2011

3- بكالوريوس في الأحياء المجهرية، قسم علوم الحياة ، كلية العلوم ، جامعة الموصل 1989

 ,2011.IC3 (880) الدورات التدريبية 1- اختبار الكمبيوتر

2- دورة اللغة الإنجليزية المكثفة - النصف الثانى (2007-2008) جامعة التكنولوجيا ماليزية

 (473 درجة) أغسطس 2011ITP TOEFL 3- شهادة

4- شهادة اتقان لغة اجنبية كلية الآداب جامعة الموصل 1991

رسائل شكر: 15

الوظائف المهنية 1- مدرس ، كلية الطب ، الجامعة. الموصل من عام 2015 حتى الآن

 مدرس بكلية طب الأسنان بالجامعة. الموصل 2015-2016

 مدرس مشارك بكلية الطب جامعة. الموصل من 2011 حتى 2014

 باحث مشارك بكلية الطب بالجامعة. الموصل 2005-2009

 باحث مشارك بكلية الطب بالجامعة. الموصل 1993-1994

 مقرر فرع التشريح , كلية الطب جامعة. الموصل من تموز 2020 حتى الآن

الخبرات العملية 1- تدريس مادة علم الفيروسات لطلبة الطب من الصف الثالث جامعتي الموصل ونينوى 2015-2016.

تدريس دروس الأحياء الطبية لطلبة الطب وطب الأسنان من الدرجة الأولى جامعة الموصل منذ 2011

العمل في المختبرات الطبية

4-تدريس الدروس العلمية والمخبرية لطلبة الصف الأول في الأحياء الطبية بكليات الطب

عضو اتحاد البيولوجيين العراقيين 1990

عدد البحوث المقيمة عالميا : اكثر من 130 بحث

البحوث والكتب المنشورة:

1. **Dawood A,** Altobje M, and Alnori H**.** Compatibility of the Ligand Binding Sites in the Spike Glycoprotein of
2. COVID-19 with those in the Aminopeptidase and the Caveolins 1, 2 Proteins. Res J Pharm Tech. 2021; 14(9): 4760-4766. doi:10.52711/0974-360X.2021.00828.
3. **Dawood A.** What Do You Know About the Second Wave of COVID-19? Res J Sci Tech. 2021; 13(3):218-220. doi:10.52711/2349-2988.2021.00034.
4. **Dawood A.** A New Strain of the Swine Acute Diarrhea Syndrome Coronavirus (SADS-CoV) has the Ability to Infect Human Respiratory and Intestinal Cells.  SRJ Clin & Med Sci. 2021; 1(1): 16-17. doi:10.47310/srjcms.2021.v01i01.005. . <https://mail.google.com/mail/u/0/#inbox/FMfcgzGkZkZXCLGwjqwkchQtflMzKWQV?projector=1&messagePartId=0.2>.
5. **Dawood A,** Altobje M, and Al-Rrassam Z.Adoption of Euvax-B vaccine in Nineveh. VacciMonitor. 2021; 30(2):91-95. <https://vaccimonitor.finlay.edu.cu/index.php/vaccimonitor/article/view/269>.
6. **Dawood A.** Reasons for discontinuing the use of Hydroxychloroquine in the treatment of the Novel Coronavirus. *Asi J Pharm Ana.* 2021; 11(2):179-0. doi: 10.52711/2231-5675.2021.00030. <https://ajpaonline.com/AbstractView.aspx?PID=2021-11-2-20>.
7. **Dawood A.** Using Remdesivir and Dexamethasone for Treatment of SARS-CoV-2 Shortens the patient's stay in the Hospital. *Asi J Pharm Res*. 2021; 11(2):138-0. doi: 10.52711/2231-5691.2021.00026. <https://asianjpr.com/AbstractView.aspx?PID=2021-11-2-12>.
8. **Dawood A**. The effects of the Russian Vaccine (Sputnik V) on the Volunteers. *Apollo Med*. 2021; 18(2):1-2. doi: 10.4103/am.am\_115\_20. <https://www.apollomedicine.org/preprintarticle.asp?id=316401>.
9. **Dawood A**, Altobje M, and Alrassam Z. Molecular Docking of SARS-CoV-2 Nucleocapsid Protein with Angiotensin-Converting Enzyme II. *Mikrobio Zhu.* 2021; 83(2):82-92. [doi: 10.15407/microbiolj83.02.082](https://doi:%2010.15407/microbiolj83.02.082).
10. **Dawood A**. Should we worry that the COVID-19 could be transmitted with the semen? *Curr Med Res Pract* 2021; 11:107-8. doi: 10.4103/cmrp.cmrp\_26\_20. <http://www.cmrpjournal.org/temp/CurrMedResPract112107-4964905_134729.pdf>.
11. **Dawood A.** SARS-CoV-2 is originated from Bat Corona Virus. *Res J Sc Tech.* 2021; 13(1): 31-32. doi: 10.5958/2349-2988.2021.00005.X. <https://rjstonline.com/AbstractView.aspx?PID=2021-13-1-5>.
12. **Dawood A, and Jasim B.** The CRISPR Genome Editing Process is an Effective Advancement of Short-Term Cancer Treatment. *Res J Pha Dos Fo Tech*. 2021; 13(1): 54-56. doi: 10.5958/0975-4377.2021.00009.4. <https://rjpdft.com/AbstractView.aspx?PID=2021-13-1-9>.
13. **Dawood A.** New Variant of SARS-CoV-2 in South Africa. *Prog Med Sc*. 2021; 5(1): 1-2. doi: 10.5455/pms.20211013. http://www.promedsci.org/articles/New%20Variant%20of%20SARS-CoV-2%20in%20South%20Africa.
14. **Dawood A.** Immunotherapy for Advanced Breast Cancer, An Overview Study. *Clin Med Med Res*. 2021; 2(2): 126-130. <http://www.clinicalmedicine.in/index.php/cmmr/article/view/41>.
15. **Dawood A.** COVID-19: what are the precautionary measures that you do if you travel to a country with the epidemic?. *Vet Med Pub Hea*. 2021; 2(1): 23-24. doi: 10.31559/vmph2021.2.1.4. <https://www.refaad.com/Files/GLM/VMPH-2-1-4.pdf>.
16. **Dawood A.** Identification of CTL and B-cell epitopes in the Nucleocapsid Phosphoprotein of COVID-19 using Immunoinformatics. *Microbiol J*. 2021; 83(1): 78-86. [doi: 10.15407/microbiolj83.01.078](https://doi.org/10.15407/microbiolj83.01.078). <http://microbiolj.org.ua/en/archiv/2021-tom-83/1-jan-feb-tom-83/2021-83-1-09>.
17. **Dawood A, Altobje M, and Alrassam Z.** Elevation of BSF-2 level in serum of patients with Hepatitis B Virus. *Med Immuno Russ.* 2021; 23(1): 87-94. [doi: 10.15789/1563-0625-EOB-2091](https://doi.org/10.15789/1563-0625-EOB-2091).
18. **Dawood A, and Alrassam Z.** SARS-C0V-2 in the second wave. *OA Case Rep*. 2021; 1:012: 1-3. [doi: 10.33118/oaj.rep.2021.01.012](https://doi.org/10.33118/oaj.rep.2021.01.012).
19. **Dawood A.** Transmission of SARS CoV-2 virus through the ocular mucosa worth taking precautions. *Vacunas*. 2021; 22(1):56–57. [doi: 10.1016/j.vacun.2020.09.003](https://doi.org/10.1016/j.vacun.2020.09.003).
20. **Dawood A.** Glycosylation, ligand binding sites and antigenic variations between membrane glycoprotein of COVID-19 and related coronaviruses. *Vacunas*. 2021; 22(1): 1-9. [doi: 10.1016/j.vacun.2020.09.005](https://doi.org/10.1016/j.vacun.2020.09.005).
21. **Dawood A.** Should we worry that the COVID-19 could be transmitted with the semen? *As J Pharm Res*. 2020; 10(4): 319-320. doi:10.5958/2231-5691.2020.00054.4. <https://asianjpr.com/AbstractView.aspx?PID=2020-10-4-12>.
22. **Dawood A,** Altobje M.Inhibition of N-linked Glycosylation by Tunicamycin May Contribute to The Treatment of SARS-CoV-2. *Microbiol Path*. 2020; 149:104586. [doi: 10.1016/j.micpath.2020.104586](https://doi.org/10.1016/j.micpath.2020.104586).
23. **Dawood A,** Khaleel A, and Hayawi A**.** Estimate viral RNA of Hepatitis C of β-thalassemia patients in Nineveh province. *EJMCM*. 2020; 7(10): 1-8. <https://ejmcm.com/article_2837.html>.
24. **Dawood A, and** Altobje M.Precautionary measures are taken by countries to reduce the transmission of the COVID-19. AJAMS. 2020; 2(2):29-32. <https://www.mbimph.com/index.php/AJOAIMS/article/view/1697>.
25. **Dawood A.** Genes Transfer is the Main Process for Prediction of a Drug or Vaccine Against SARS-C0V-2. *J Pathol Res Rev Res.* 2020; 2(2): 1-3. <https://www.onlinescientificresearch.com/articles/genes-transfer-is-the-main-process-for-prediction-of-a-drug-or-vaccine-against-sarsc0v2.pdf>.
26. **Dawood A**, and Yousif W. The Main Reasons Why Cancer Is So Difficult To Treatment. *AJAMS*. 2020; 2(2): 20-22. <https://mbimph.com/index.php/AJOAIMS/article/view/1693>.
27. **Dawood A.** AstraZeneca Pause Temporary the Vaccine of SARS-CoV-2, (AZD1222) and Resumption of the Third Phase Trials. *J Inf Dis Med*. 2020; 5:1. <https://doi:10.37421/jidm.2020.5.S1>.<https://www.hilarispublisher.com/open-access/astrazeneca-pause-temporary-the-vaccine-of-sarscov2-azd1222-and-resumption-of-the-third-phase-trials.pdf>.
28. **Dawood A,** Alnori H. Tunicamycin Anticancer Drug May Reliable to Treat Coronavirus Disease-19. *OAMJMS*. 2020; 8(T1):129-133. [doi: 10.3889/oamjms.2020.4954](https://doi.org/10.3889/oamjms.2020.4954).
29. **Dawood A**. Chickenpox, Review and Prevalence Varicella virus in Nineveh Province. *AJAMS*. 2020; 2(1):6-14. <https://mbimph.com/index.php/AJOAIMS/article/view/1548/1480>.
30. **Dawood A.** Mutated COVID-19, May Foretells Mankind in a Great Risk in The Future. *N Mic N Inf.* 2020; Vol. (35). [doi: 10.1016/j.nmni.2020.100673](https://doi.org/10.1016/j.nmni.2020.100673).
31. **Dawood A.** Hepatitis B Virus, Overview, Novel Genotypes and Subtypes. Latvia: Lap Lambert Academic Publishing; 2019;11.[https://www.morebooks.de/store/gb/book/hepatitis-b-virus,-overview,-novel-genotypes-and-subtypes/isbn/978-620-0-47793-4](https://www.morebooks.de/store/gb/book/hepatitis-b-virus%2C-overview%2C-novel-genotypes-and-subtypes/isbn/978-620-0-47793-4).
32. **Dawood A.** Different vectors used to transform and clone of nonstructural NS1 gene of Influenza B in *Escherichia coli*. *I J Vet Sci.* 2019; 33(2):329-333. doi: [10.33899/ijvs.2019.162964](http://dx.doi.org/10.33899/ijvs.2019.162964). <https://vetmedmosul.com/article_162964.html>.
33. **Dawood A,** andAltobjeM. Correlation between CXCL-motif-10 and IFN- γ on Hemodialysis Patients with HCV under Treatment, *Int J Eme Tech*. 2019;10(3): 208-215. <https://www.researchtrend.net/ijet/current_issue_ijet.php?taxonomy-id=64>.
34. **Dawood A.** Hasan G, Hayawi A. Determination Genotype D of Hepatitis B Virus amongst Patients in Mosul-Iraq. *Int J Sci & Tech Res*. 2019; 8(9): 1218-1220. <https://www.ijstr.org/research-paper-publishing.php?month=sep2019>.
35. **Dawood** A. Impact of Serum Interleukin 6 (IL-6) Level of Patients with Acute & Chronic Hepatitis B Virus. *Biological Forum*. 2019; 11(1): 248-254. <https://www.researchtrend.net/bfij/current_issue_bfij.php?taxonomy-id=54>
36. **Dawood A,** AltobjeM, and Thanoon E.Assessment Association between IFN-β2, AST and Natural Course of Infections with Hepatitis A and C Viruses. *J Inf Dis Med*. 2019; 4(1): 1-7. <https://www.hilarispublisher.com/abstract/assessment-association-between-ifn-beta2-ast-and-natural-course-of-infections-with-hepatitis-a-and-c-viruses-25020.html>.
37. **Dawood** A, Thanoon E, and Mohammed, F. Prevalence of Hepatitis B Virus Markers amongst Patients in Mosul-Iraq. *Int J Nov Res Li Sci*. 2019; 6(1): 27-31. <https://www.noveltyjournals.com/issue/IJNRLS/Issue-1-January-2019-February-2019>.
38. **Dawood** **A**. Detection Subtype (AYW) of Hepatitis B Virus amongst Patients in Mosul-Iraq. *Int J Nov Res Li Sci.* 2015; 2(4): 65-68. <https://www.noveltyjournals.com/issue/IJNRLS/Issue-4-July-2015-August-2015>.
39. **Al-Fahady**, N, and **Dawood, A.** Effect working of cars painting workers on some Biochemical characteristics from blood, *Tikrit Journal of Pure Science*. 2012; 17(1):11-16. <https://www.iasj.net/iasj/download/a091411ea7f03b4c>.
40. **Dawood**, **A**. Cloning of Influenza B NS1 gene in *Escherichia coli*. Master dissertation, University Technology Malaysia. 2011. <http://eprints.utm.my/id/eprint/12283/>.